Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

13 enrolled

Breast

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms

NCT05868226 2025-04-04

PRE-I-SPY-PI

Phase 1 Recruiting

124 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05748834 2025-01-31

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Recruiting

36 enrolled

Breast

Breast Neoplasms

NCT06162559 2024-01-11

TRAIN-4

Phase 1 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast

Breast Neoplasms

NCT04896320 2023-06-22

2019-101826

Phase 1/2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast

Breast Neoplasms